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A B S T R A C T
Vandetanib is an orally available tyrosine kinase inhibitor used in the treatment of cancer. The current synthesis proceeds
via an unstable 4-chloroquinazoline, using harsh reagents, in addition to requiring sequential protection and deprotection
steps. In the present work, use of the Dimroth rearrangement in the key quinazoline forming step enabled the synthesis of
Vandetanib in nine steps (compared to the previously reported 12–14).
© 2016 Published by Elsevier Ltd.
Introduction
Vandetanib (Caprelsa™), discovered by AstraZeneca, is an orally
available tyrosine kinase inhibitor with activity against VEGFR2/
EGFR/RET which is currently used in the treatment of medullary thy-
roid cancer (Fig. 1).1 Vandetanib is representative of a wide class
of 4-anilinoquinazoline drug molecules that function as adenosine
mimetics and bind at the tyrosine kinase intracellular receptor site;
other examples of this compound class include Erlotinib and Gefitinib
(Fig. 1).1,2 As part of a programme of work investigating the use of
tyrosine kinase inhibitors (TKI’s) for application to Positron Emission
Tomography (PET) imaging of receptor expression, the improved syn-
thesis of Vandetanib and related compounds was investigated.
The current literature precedence for the synthesis of Vandetanib
via the quinazolinone intermediate 3 is summarised in Scheme 1
(shown in more detail in ESI, Scheme S1). This is a time-consuming
synthetic strategy involving twelve steps overall and harsh reagents/
reaction conditions. The original synthesis utilised amide 1,3 which
requires pre-preparation due to a lack of commercial availability and
Gold’s reagent ([3-(dimethylamino)-2-azaprop-2-en-1-ylidene]di-
methylammonium chloride) to directly construct 3 (Scheme 1).4–6
More recent patents have avoided the use of Gold’s reagent and pro
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ceeded via benzoic acid 2; however, this still involves progression
through multiple protection and deprotection steps.4 The current work
reports a new and improved synthesis of Vandetanib, avoiding quina-
zolinone 3 and utilising the Dimroth rearrangement for a streamlined
synthetic procedure.7–10
Results and discussion
The synthesis commenced from the inexpensive building block
4-hydroxy-3-methoxybenzonitrile 4 (Scheme 2), which was alkylated
with benzyl bromide in quantitative yield without the need for exten-
sive purification.11 Nitration of 5 under mild conditions afforded 6 in
93% yield as a yellow precipitate which required no further purifica-
tion.
Literature precedence for the reduction of 6 using iron and am-
monium formate, revealed a difficult work-up, associated with poor
yields;12 alternative literature procedures suggested the use of sodium
dithionite.13 Pleasingly, reduction using sodium dithionite gave 7 in
74% yield, with no purification required (Scheme 2). The synthesis of
8 (Scheme 2 and Table 1) was troublesome due to the poor solubil-
ity of aniline 7 in organic solvents. Ultimately the reaction was per-
formed neat with a large excess of DMF-DMA to aid solubility and
formation of the formamidine; toluene was also tested as a co-solvent
with no observable effect on the reaction progress. Microwave irradi-
ation for 15 minutes at 90 °C (Entry 1) afforded only minimal conver-
sion to formamidine 8; however, extension of the reaction time by a
further 15 minutes (to a total of 30 minutes) resulted in an improved
yield of 95% (Entry 5) due to the increased time for solubilisation in
http://dx.doi.org/10.1016/j.tetlet.2017.02.082
0040-4039/© 2016 Published by Elsevier Ltd.
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Fig. 1. Structures of Vandetanib (Caprelsa™), Gefitinib (Iressa™) and Erlotinib
(Tarceva™).
Scheme 1. Current synthetic procedure to Vandetanib via the key quinazolinone inter-
mediate 3.
Scheme 2. Reagents and conditions: i) Benzyl bromide, K2CO3, DMF, rt, 18 h; ii) Ni-
tric acid, Ac2O, 0 °C to rt, 18 h; iii) NaHCO3, tetra-butyl ammonium chloride, Sodium
dithionite, DCM, water, rt, 2 h; iv) DMF-DMA, microwave, 90 °C, 15 min.
Table 1
Optimisation for the synthesis of 8.
Entry Solvent
Time
(min) Heating (temp(°C))
Work-
up Yield
1 DMF-DMA 15 Microwave (90 °C) A 2%
2 DMF-DMA-
toluene
120 Conventional
(185 °C)∗
None 58%
3 DMF-DMA-
toluene
30 Microwave (90 °C) A 95%
4 DMF-DMA-
toluene
30 Microwave (90 °C) B 94%
5 DMF-DMA 30 Microwave (90 °C) A or B 94–95%
A) Allowed to precipitate overnight; B) Removal of DMF-DMA using silica
chromatography; ∗Distillation facilitated removal of DMF-DMA from the product.
Reagents and conditions: 7 (500 mg, 1.97 mmol), either DMF-DMA (3 mL) or
DMF-DMA in toluene (1:1); C) Microwave reactions were conducted in a Biotage
Initiator with a maximum power output of 400 W.
DMF-DMA to occur. Conventional heating (Entry 2) at the same tem-
perature provided 8 in a reduced yield of 58% despite extending the
reaction time to 120 minutes. Of note, on smaller scales chromato-
graphic removal of DMF-DMA was required, but on larger scales (e.g.
8 mmol) formamidine 8 was observed to precipitate from DMF-DMA.
TFA mediated debenzylation of 8 was selected owing to the po-
tential vulnerability to hydrogenation induced reduction of the for-
mamidine, and afforded 9 in an almost quantitative yield. Alkyla-
tion of 9 afforded 10 in 58% yield using tert-butyl-4-(tosy
loxy)methyl)piperidine-1-carboxylate (A in Scheme 3), which was
synthesised according to a literature method.14
The key Dimroth rearrangement step was then investigated com-
mencing from 10 in the presence of 4-bromo-3-fluoroaniline
(1 equiv.) and acetic acid with microwave heating at 130 °C for
45 min. No product was observed by either TLC or LCMS when irra-
diated for 15 minutes at 118 °C; this contrasted with previous reports
on the synthesis of related 4-anilinoquinazolines such as Gefitinib.15,16
Duration of the microwave irradiation was irrelevant for the synthe-
sis of 11, which was temperature dependent and required 130 °C for
complete conversion, highlighting the possible inactivated nature of
the reagents. Quinazoline 11 was isolated in 62% yield after chromato-
graphic purification. The proposed mechanism for this rearrangement
is illustrated in Scheme 4.
The penultimate step in the synthesis of Vandetanib was the BOC
deprotection of piperidine 11. Deprotection according to literature
procedures resulted in low yields during aqueous work-up (Scheme
5).3 However, through following the literature deprotection procedure4
and avoiding aqueous work-up, direct silica chromatography purifi-
cation afforded 12 in 83% yield. Reductive amination with formalde-
hyde according to the literature procedure4 yielded Vandetanib
(Caprelsa™) in 84% yield, an overall 7% yield over nine steps.
Conclusion
In this report we have presented an alternative route to the synthe-
sis of Vandetanib via the Dimroth rearrangement. Ultimately this new
synthetic procedure is a reduction of three steps compared to the most
concise published method and avoids the series of protection and de-
protection steps currently established by several literature procedures.
Chromatography is only required for four steps in this synthesis com-
pared to multiple steps in the previous reports. Overall Vandetanib
was synthesised in 7% yield over 9 steps compared to 4–20% yield
over 12–14 steps in the previously reported methods.
Experimental
Experimental data can be found in the Supplementary data file as-
sociated with this report. In addition to experimental information and
characterisation data this file also contains NMR spectra for selected
compounds.
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Scheme 3. Reagents and conditions: i) TFA, microwave (max. power 400 W), 70 °C,
45 min; ii) A, Cs2CO3, MeCN, reflux, 3 hr; iii) 4-bromo-2-fluoroaniline, 130 °C, 1 h.
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Scheme 4. Proposed mechanism for the Dimroth rearrangement; derived from Chandregowdra and co-workers in their synthesis of Erlotinib and Gefitinib.16
Scheme 5. i) TFA, DCM, rt, 2 h; ii) HCHO, AcOH, NaBH(OAc)3, MeOH, DCM, rt, 2 h.
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